Adults with type 1 diabetes who drink a minimum of five cups of coffee per day could have an increased risk of metabolic syndrome compared with those who drink less, researchers suggest.
These findings from scientists at the University of Helsinki, Finland, are the latest in a multitude of studies which have reviewed the relationship between coffee, diabetes and metabolism in recent years.
Last year, drinking more coffee was shown to reduce the risk of death in an international study, including among people with diabetes. Also in 2017, regular coffee intake was reported to lower the risk of type 2 diabetes.
While this new study indicates heightened coffee consumption among people with type 1 diabetes may confer negative health aspects, future studies will need to explore and validate this association.
The researchers evaluated data from 1,040 adults with type 1 diabetes who were divided into four groups based on their coffee consumption, and determined potential associations regarding metabolic syndrome.
Moderate (3-5 cups per day) and high (5+) coffee consumption increased the odds of metabolic syndrome, which was categorised by possessing at least three cardiovascular riskfactors: obesity, high blood pressure, high blood sugar levels, high triglyceride levels and/or low HDL-cholesterol.
These findings remained regardless of age, sex, energy intake, alcohol intake, smoking or physical activity. Moreover, increasing coffee intake was also shown to impair insulin resistance among participants.
But researchers stressed this is an association at most, and not intended as a warning for people with type 1 diabetes to drastically reduce or cut out their coffee consumption.
“Whether habitual coffee consumption will have any negative or beneficial effects on health outcomes, in this population of patients with type 1 diabetes, will be assessed in future studies,” said the researchers.
The findings appear online in the journal Nutrition, Metabolism and Cardiovascular Diseases.
Business Front: Insulet appears to be doing well on the business side these days. New patient starts were up 20% this past year, while new pediatric patients were up a full 30% over the previous year. So more patients are starting the OmniPod than ever before, it seems. Insulet CEO Pat Sullivan says the company now has a total 85,000 OmniPod users, as of the end of 2015.
Insulet sold its Neighborhood Diabetes Business (the mail order medical supply company it acquired a few years ago) to Liberty Medical early this month, meaning those OmniPod customers who used Neighborhood Diabetes as a durable medical equipment provider will now be switched to Liberty.
Higher Concentrated-Insulin Pods: Insulet’s excited about its partnership with Eli Lilly for developing OmniPod devices that will have both the concentrated U-200 and U-500insulins inside. They’re queuing up a clinical study the U-500 version now, and already have a third of the required patients signed up. Insulet expects both of these new Pods to be available in the next 2 or 3 years, offering more choice for PWDs who may need more insulin.